FDA approves Novartis's Cosentyx for polymyalgia rheumatica, the first IL-17 drug for the disease
The FDA approved Novartis's Cosentyx 150 mg for polymyalgia rheumatica (PMR) in adults who do not respond to steroids or cannot tolerate tapering. The approval was based on the REPLENISH trial, where 40.5% of patients achieved sustained remission compared to 20.5% on placebo. Cosentyx sales were $1.857 billion in Q3, up 9% at constant currency.
How this was made
The 30-second read
Why it matters
The approval provides a new revenue stream and may lift Novartis's stock as investors price in the expanded market.
Market read
Regulatory approval of a major drug adds material upside potential for Novartis and signals broader interest in IL‑17 therapies.
What to watch
Reimbursement negotiations and pricing uncertainty for the new PMR indication.
Background
Novartis announced FDA approval of its IL‑17 biologic Cosentyx for polymyalgia rheumatica, expanding the drug to its 11th U.S. indication.
Ticker impact
FDA approved Novartis's Cosentyx 150 mg for polymyalgia rheumatica, the first IL‑17 drug for the disease.
upward pressure as investors price in expanded market opportunity for Cosentyx.
Regulatory approval is a primary catalyst; the drug already generates $1.9 B in Q3 sales and the new indication opens a sizable US patient base.
Market effects
Strengthens biotech and pharma sector, especially companies with IL‑17 pipelines.
U.S. equities likely see a modest lift, particularly healthcare indexes.
Global markets may react as the indication is approved in the EU and under review in Japan.
Counterpoint
Potential safety concerns and competition from existing IL‑6 therapy Kevzara could limit uptake.
Key entities
- companyNovartis AG
Swiss pharmaceutical company, ticker NVS.
- productCosentyx (secukinumab)
IL‑17A inhibitor now approved for PMR.




